Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl) pyrimidines

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4103-4106

  Sharma, Sameer ^a   Kedrowski, Jeffrey ^a   Rook, Jerri M ^a   Smith, Randy L ^a   Jones, Carrie K ^a,b   Rodriguez, Alice L ^a,b   Conn, P Jeffrey ^a,b   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (PHENYLETHYNYL)PYRIMIDINE DERIVATIVE; 2 BROMOPYRIMIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 METHYLPHENYLACETYLENE; 4 METHYLPHENYLACETYLENE; 5 (PHENYLETHYNYL)PYRIMIDINE DERIVATIVE; 5 BROMOPYRIMIDINE; AMPHETAMINE; BROMINE DERIVATIVE; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; PHENYLACETYLENE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ALLOSTERIC REGULATION; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; PYRIMIDINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67650729937     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900654c     Document Type: Article

References (21)

1. Schoepp, D. D.; Jane, D. E.; Monn, J. A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38, 1431-1476.
2. Conn, P. J.; Pin, J. P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237.
3. Gasparini, F.; Lingenhohl, K.; Stoehr, N.; Flor, P. J.; Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M. A.; Johnson, E. C.; Hess, S. D.; Rao, S. P.; Sacaan, A. I.; Santori, E. M.; Velicelebi, G.; Kuhn, R. 2-Methyl-6-(phenylethynyl)-pyrimidine (MPEP), a potent, selective and systemically active mGluR5 receptor antagonist. Neuropharmacology 1999, 38, 1493-1503.
4. Roppe, J. R.; Wang, B.; Huang, D.; Tehrani, L.; Kamenecka, T.; Schweiger, E. J.; Anderson, J. J.; Brodkin, J.; Jiang, X.; Cramer, M.; Chung, J.; Reyes-Manalo, G.; Munoz, B.; Cosford, N. D. P. 5-[(2-Methyl-1,3-thiazol-4-yl) ethynyl]-2,3′-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGluR5) receptor antagonist with anxiolytic activity. Bioorg. Med. Chem. Lett. 2004, 14, 3993-3996.
5. Lea, P. M.IV; Faden, A. I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 2006, 12, 149-166.
6. Tatarczynska, E.; Klodzinska, A.; Chojnacka,-Wojcik, E.; Palucha, A.; Gasparini, F.; Kuhn, R.; Pilc, A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGluR5 receptor antagonist. Br. J. Pharmacol. 2001, 132, 1423-1430.
7. Yan, Q. J.; Rammal, M.; Tranfaglia, M.; Bauchwitz, R. P. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49, 1053-1066.
8. Porter, R. H. P.; Jaeschke, G.; Spooren, W.; Ballard, T. M.; Buttelmann, B.; Kolczewski, S.; Peters, J. U.; Prinseen, E.; Wichman, J.; Vieira, E.; Muhlemann, A.; Gatti, S.; Mutel, V.; Malherbe, P. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 2005, 315, 711-721.
9. O'Brien, J. A.; Lemaire, W.; Chen, T. B.; Chang, R. S. L.; Jacobson, M. A.; Ha, S. N.; Lindsley, C. W.; Sur, C.; Pettibone, D. J.; Conn, P. J.; Williams, D. L. A family of highly selective allosteric modulators of the metabotropic glutamate subtype 5. Mol. Pharmacol. 2003, 64, 731-740.
10. Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'Brien, J. A.; Lemiare, W.; Williams, D. L.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.; Smith, S.; Duggan, M. E.; Hartman, G. D.; Conn, P. J.; Huff, J. R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5- yl)benzamides that potentiate receptor function in vivo. J. Med. Chem. 2004, 47, 5825-5828.
11. Kinney, G. G.; O'Brien, J. A.; Lemaire, W.; Burno, M.; Bickel, D. J.; Clements, M. K.; Wisnoski, D. D.; Lindsley, C. W.; Tiller, P. R.; Smith, S.; Jacobson, M. A.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Williams, D. W. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 2005, 313, 199-206.
12. O'Brien, J. A.; Lemaire, W.; Wittman, M.; Jacobson, M. A.; Ha, S. N.; Wisnoski, D. D.; Lindsley, C. W.; Wisnoski, D. D.; Schaffhauser, H. J.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Conn, P. J.; Williams, D. L. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther. 2004, 309, 568-577.
13. (a) Farina, M.; Gagliardi, S.; Le Poul, E.; Mutel, V.; Palombi, G.; Poli, S. M.; Rocher, J.-P. Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors and Their Preparation, Pharmaceutical Compositions and Use in the Teatment of Central and Peripheral Nervous System Disorders. WO123255, 2006.
14. (b) Epping-Jordan, M.; Le Poul, M.; Rocher, J. P. Allosteric modulation: a novel approach to drug discovery. Innovations Pharm.Technol. 2007, 24, 24-26.
15. Engers, D. W.; Rodriguez, A. L.; Oluwatola, O.; Hammond, A. S.; Venable, D. F.; Williams, R.; Sulikowski, G. A.; Conn, P. J.; Lindsley, C. W. Synthesis, SAR and unanticipated pharmacological profiles of analogs of the mGluR5 ago-potentiator ADX-47273. ChemMedChem 2009, 4, 505-511.
16. Rodriguez, A. L.; Nong, Y.; Sekaran, N. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts a neutral allosteric site ligandonmetabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 2005, 68, 1793-1802.
17. Sharma, S.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Synthesis and SAR of a mGlu5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl) pyrimidine scaffold. Bioorg. Med. Chem. Lett. 2008, 18, 4098-5101.
18. Kennedy, J. P.; Williams, L.; Bridges, T. M.; Daniels, R. N.; Weaver, D.; Lindsley, C. W. Application of combinatorial chemistry science on modern drug discovery. J. Comb. Chem. 2008, 10, 345-354.
19. For full description of the 24-member library, see Supporting Information.
20. Leister, W.; Strauss, K.; Wisnoski, D.; Zhao, Z.; Lindsley, C. Development of a custom high-throughput preparative liquid chromaotgraphy/mass spectrometer platform for the preparative purification and anlaytical analysis of comound libraries. J. Comb. Chem. 2003, 5, 322-329.
21. Busse, C. S.; Brodkin, J.; Tattersall, D.; Anderson, J. J.; Warren, N.; Tehrani, L.; Bristow, L. J.; Varney, M. A.; Cosford, N. D. P. The behavioral profile of the potent and selective mGluR5 receptor anatgonist 3-[(2- methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004, 29, 1971-1979.